Modulation of mitochondrial permeability transition pores in reperfusion injury: Mechanisms and therapeutic approaches.
calcium
cardiovascular diseases
mitochondria
permeability transition pore
subunit c
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
03
07
2024
accepted:
24
09
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
Ischemia/reperfusion injury is attracting continuous interest in science for two reasons: because it affects several clinical conditions and because it has been identified, albeit in broad terms, the molecular entity becoming activated by the reperfusion damage paradoxes. Indeed, calcium, oxygen-dependent oxidative stress and pH would activate conformational changes in the mitochondrial cristae embedded F
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14331Subventions
Organisme : Associazione Ricerca Oncologica Sperimentale Estense
Organisme : Local funds from the University of Ferrara
Organisme : Ministero della Salute
ID : GR-2018-12367114
Organisme : Ministero della Salute
ID : GR-2019-12369862
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG-23670
Informations de copyright
© 2024 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transduct Target Ther. 2023;8(1):333.
Morciano G, Boncompagni C, Ramaccini D, et al. Comprehensive analysis of mitochondrial dynamics alterations in heart diseases. Int J Mol Sci. 2023;24(4):3414.
Giorgi C, Marchi S, Pinton P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat Rev Mol Cell Biol. 2018;19(11):713‐730.
Pickles S, Vigié P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. Curr Biol. 2018;28(4):170‐185.
Bonora M, Giorgi C, Pinton P. Molecular mechanisms and consequences of mitochondrial permeability transition. Nat Rev Mol Cell Biol. 2022;23(4):266‐285.
Haworth RA, Hunter DR. The Ca2+−induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys. 1979;195(2):460‐467.
Morciano G, Giorgi C, Bonora M, et al. Molecular identity of the mitochondrial permeability transition pore and its role in ischemia‐reperfusion injury. J Mol Cell Cardiol. 2015;78:142‐153.
Baines CP. The mitochondrial permeability transition pore and ischemia‐reperfusion injury. Basic Res Cardiol. 2009;104(2):181‐188.
Gerle C. Mitochondrial F‐ATP synthase as the permeability transition pore. Pharmacol Res. 2020;160:105081.
Nesci S, Trombetti F, Ventrella V, Pagliarani A. From the Ca2+−activated F1FO‐ATPase to the mitochondrial permeability transition pore: an overview. Biochimie. 2018;152:85‐93.
Vlasov AV, Osipov SD, Bondarev NA, et al. ATP synthase FOF1 structure, function, and structure‐based drug design. Cell Mol Life Sci. 2022;79(3):179.
Lai Y, Zhang Y, Zhou S, et al. Structure of the human ATP synthase. Mol Cell. 2023;83(12):2137‐2147.
Walker JE, Lutter R, Dupuis A, Runswick MJ. Identification of the subunits of F1F0‐ATPase from bovine heart mitochondria. Biochemistry. 1991;30(22):5369‐5378.
Meyer B, Wittig I, Trifilieff E, Karas M, Schägger H. Identification of two proteins associated with mammalian ATP synthase. Mol Cell Proteomics. 2007;6(10):1690‐1699.
Alavian KN, Beutner G, Lazrove E, et al. An uncoupling channel within the c‐subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci USA. 2014;111(29):10580.
Giorgio V, von Stockum S, Antoniel M, et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci USA. 2013;110(15):5887‐5892.
Urbani A, Giorgio V, Carrer A, et al. Purified F‐ATP synthase forms a Ca2+−dependent high‐conductance channel matching the mitochondrial permeability transition pore. Nat Commun. 2019;10(1):4341.
Mnatsakanyan N, Llaguno MC, Yang Y, et al. A mitochondrial megachannel resides in monomeric F1FO ATP synthase. Nat Commun. 2019;10(1):5823.
Bonora M, Bononi A, De Marchi E, et al. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. Cell Cycle. 2013;12(4):674‐683.
Bonora M, Morganti C, Morciano G, et al. Mitochondrial permeability transition involves dissociation of F1FO ATP synthase dimers and C‐ring conformation. EMBO Rep. 2017;18(7):1077‐1089.
Galber C, Minervini G, Cannino G, et al. The f subunit of human ATP synthase is essential for normal mitochondrial morphology and permeability transition. Cell Rep. 2021;35(6):109111.
Carraro M, Giorgio V, Šileikytė J, et al. Channel formation by yeast F‐ATP synthase and the role of dimerization in the mitochondrial permeability transition. J Biol Chem. 2014;289(23):15980‐15985.
Carraro M, Jones K, Sartori G, et al. The unique cysteine of F‐ATP synthase OSCP subunit participates in modulation of the permeability transition pore. Cell Rep. 2020;32(9):108095.
Giorgio V, Burchell V, Schiavone M, et al. Ca2+ binding to F‐ATP synthase β subunit triggers the mitochondrial permeability transition. EMBO Rep. 2017;18(7):1065‐1076.
Antoniel M, Jones K, Antonucci S, et al. The unique histidine in OSCP subunit of F‐ATP synthase mediates inhibition of the permeability transition pore by acidic pH. EMBO Rep. 2018;19(2):257‐268.
Guo L, Carraro M, Sartori G, et al. Arginine 107 of yeast ATP synthase subunit g mediates sensitivity of the mitochondrial permeability transition to phenylglyoxal. J Biol Chem. 2018;293(38):14632‐14645.
Morciano G, Pedriali G, Bonora M, et al. A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients. Cell Rep. 2021;35(2):108983.
Pinke G, Zhou L, Sazanov LA. Cryo‐EM structure of the entire mammalian F‐type ATP synthase. Nat Struct Mol Biol. 2020;27(11):1077‐1085.
Elustondo PA, Nichols M, Negoda A, et al. Mitochondrial permeability transition pore induction is linked to formation of the complex of ATPase C‐subunit, polyhydroxybutyrate and inorganic polyphosphate. Cell Death Dis. 2016;2:16070.
Elustondo PA, Angelova PR, Kawalec M, et al. Polyhydroxybutyrate targets mammalian mitochondria and increases permeability of plasmalemmal and mitochondrial membranes. PLoS One. 2013;8(9):e75812.
Carroll J, He J, Ding S, Fearnley IM, Walker JE. Persistence of the permeability transition pore in human mitochondria devoid of an assembled ATP synthase. Proc Natl Acad Sci USA. 2019;116(26):12816‐12821.
He J, Ford HC, Carroll J, Ding S, Fearnley IM, Walker JE. Persistence of the mitochondrial permeability transition in the absence of subunit c of human ATP synthase. Proc Natl Acad Sci USA. 2017;114(13):3409‐3414.
He J, Carroll J, Ding S, Fearnley IM, Walker JE. Permeability transition in human mitochondria persists in the absence of peripheral stalk subunits of ATP synthase. Proc Natl Acad Sci USA. 2017;114(34):9086‐9091.
Neginskaya MA, Morris SE, Pavlov EV. Refractive index imaging reveals that elimination of the ATP synthase C subunit does not prevent the adenine nucleotide translocase‐dependent mitochondrial permeability transition. Cells. 2023;12(15):1950.
Neginskaya MA, Solesio ME, Berezhnaya EV, et al. ATP synthase C‐subunit‐deficient mitochondria have a small cyclosporine A‐Sensitive Channel, but lack the permeability transition pore. Cell Rep. 2019;26(1):11‐17.
Halestrap AP, Brenner C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem. 2003;10(16):1507‐1525.
Amodeo GF, Lee BY, Krilyuk N, et al. C subunit of the ATP synthase is an amyloidogenic calcium dependent channel‐forming peptide with possible implications in mitochondrial permeability transition. Sci Rep. 2021;11(1):8744.
Palmer DN, Fearnley IM, Walker JE, et al. Mitochondrial ATP synthase subunit c storage in the ceroid‐lipofuscinoses (batten disease). Am J Med Genet. 1992;42(4):561‐567.
Morciano G, Naumova N, Koprowski P, et al. The mitochondrial permeability transition pore: an evolving concept critical for cell life and death. Biol Rev Camb Philos Soc. 2021;96(6):2489‐2521.
Karch J, Bround MJ, Khalil H, et al. Inhibition of mitochondrial permeability transition by deletion of the ANT family and CypD. Sci Adv. 2019;5:4597.
Neginskaya MA, Morris SE, Pavlov EV. Both ANT and ATPase are essential for mitochondrial permeability transition but not depolarization. iScience. 2022;18:105447.
Algieri C, Trombetti F, Pagliarani A, et al. Mitochondrial Ca2+ −activated F1 FO ‐ATPase hydrolyzes ATP and promotes the permeability transition pore. Ann N Y Acad Sci. 2019;1457(1):142‐157.
Amanakis G, Sun J, Fergusson MM, et al. Cysteine 202 of cyclophilin D is a site of multiple post‐translational modifications and plays a role in cardioprotection. Cardiovasc Res. 2021;117(1):212‐223.
Bello D, Einhorn A, Kaushal R, et al. Cardiac magnetic resonance imaging: infarct size is an independent predictor of mortality in patients with coronary artery disease. Magn Reson Imaging. 2011;29(1):50‐56.
Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3‐year mortality with and without revascularization. J Am Coll Cardiol. 1993;22(4):984‐997.
Briston T, Selwood DL, Szabadkai G, Duchen MR. Mitochondrial permeability transition: a molecular lesion with multiple drug targets. Trends Pharmacol Sci. 2019;40(1):50‐70.
Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nat Rev Cardiol. 2019;16(1):33‐55.
Ferrari R, Balla C, Malagù M, et al. Reperfusion damage ‐ a story of success, failure, and Hope. Circ J. 2017;81(2):131‐141.
Weisz G, Généreux P, Iñiguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER‐PCI): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet. 2016;387(10014):136‐145.
Morrow DA, Scirica BM, Karwatowska‐Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non‐ST‐elevation acute coronary syndromes: the MERLIN‐TIMI 36 randomized trial. JAMA. 2007;297(16):1775‐1783.
Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J‐WIND): two randomised trials. Lancet. 2007;370(9597):1483‐1493.
Effect of 48‐h intravenous trimetazidine on short‐ and long‐term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double‐blind, placebo‐controlled, randomized trial. Effect of 48‐h intravenous trimetazidine on short‐ and long‐term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. A double‐blind, placebo‐controlled, randomized trial. Eur Heart J. 2000;21(18):1537‐1546.
Campo G, Morciano G, Pavasini R, et al. Fo ATP synthase C subunit serum levels in patients with ST‐segment elevation myocardial infarction: preliminary findings. Int J Cardiol. 2016;15(221):993‐997.
Morciano G, Preti D, Pedriali G, et al. Discovery of novel 1,3,8‐Triazaspiro[4.5]decane derivatives that target the c subunit of F1/FO‐adenosine triphosphate (ATP) synthase for the treatment of reperfusion damage in myocardial infarction. J Med Chem. 2018;61(16):7131‐7143.
Morciano G, Pedriali G, Mikus E, et al. Similarities between fibroblasts and cardiomyocytes in the study of the permeability transition pore. Eur J Clin Investig. 2022;52(7):e13764.
Fantinati A, Morciano G, Turrin G, et al. Identification of small‐molecule urea derivatives as PTPC modulators targeting the c subunit of F1/Fo‐ATP synthase. Bioorg Med Chem Lett. 2022;15(72):128822.
Pedriali G, Ramaccini D, Bouhamida E, et al. 1,3,8‐Triazaspiro[4.5]decane derivatives inhibit permeability transition pores through a FO‐ATP synthase c subunit Glu119‐independent mechanism that prevents Oligomycin A‐related side effects. Int J Mol Sci. 2023;24(7):6191‐6204.
Turrin G, Lo Cascio E, Giacon N, et al. Spiropiperidine‐based Oligomycin‐analog ligands to counteract the ischemia‐reperfusion injury in a renal cell model. J Med Chem. 2024;67(1):586‐602.
Nikolaou PE, Lambrinidis G, Georgiou M, et al. Hydrolytic activity of mitochondrial F1FO‐ATP synthase as a target for myocardial ischemia‐reperfusion injury: discovery and in vitro and in vivo evaluation of novel inhibitors. J Med Chem. 2023;66(22):15115‐15140.
Schiene‐Fischer C, Fischer G, Braun M. Non‐immunosuppressive Cyclophilin inhibitors. Angew Chem Int Ed Engl. 2022;61(39):e202201597.
Zhang CX, Cheng Y, Liu DZ, et al. Mitochondria‐targeted cyclosporin a delivery system to treat myocardial ischemia reperfusion injury of rats. J Nanobiotechnology. 2019;17(1):18.
Ikeda G, Matoba T, Nakano Y, et al. Nanoparticle‐mediated targeting of cyclosporine a enhances cardioprotection against ischemia‐reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci Rep. 2016;10(6):20467.
Halestrap AP, Connern CP, Griffiths EJ, Kerr PM. Cyclosporin a binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol Cell Biochem. 1997;174(1–2):167‐172.
Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373(11):1021‐1031.
Ottani F, Latini R, Staszewsky L, et al. Cyclosporine a in Reperfused myocardial infarction: the multicenter, controlled, open‐label CYCLE trial. J Am Coll Cardiol. 2016;67(4):365‐374.
Morciano G, Patergnani S, Pedriali G, et al. Impairment of mitophagy and autophagy accompanies calcific aortic valve stenosis favoring cell death and the severity of disease. Cardiovasc Res. 2021;118:2548‐2559.
Pedriali G, Morciano G, Patergnani S, et al. Aortic valve stenosis and mitochondrial dysfunctions: clinical and molecular perspectives. Int J Mol Sci. 2020;21(14):4899.
Chiari P, Angoulvant D, Mewton N, et al. Cyclosporine protects the heart during aortic valve surgery. Anesthesiology. 2014;121(2):232‐238.
Butt N, Bache‐Mathiesen LK, Nordrehaug JE, et al. Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to primary percutaneous coronary intervention, does not affect the levels of pro‐inflammatory cytokines or acute‐phase proteins. Cardiology. 2017;138(2):122‐132.
Atar D, Arheden H, Berdeaux A, et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST‐elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2015;36(2):112‐119.
Schaller S, Paradis S, Ngoh GA, et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther. 2010;333(3):696‐706.
Šileikytė J, Blachly‐Dyson E, Sewell R, et al. Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (translocator protein of 18 kDa (TSPO)). J Biol Chem. 2014;289(20):13769‐13781.
Campo G, Pavasini R, Morciano G, et al. Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST‐segment elevation myocardial infarction: a meta‐analysis of randomized clinical trials. Int J Cardiol. 2017;1(244):59‐66.
Kheyar A, Ahnou N, Ahmed‐Belkacem A, et al. The novel cyclophilin inhibitor C105SR reduces hepatic ischaemia‐reperfusion injury via mitoprotection. JHEP Rep. 2023;5(11):100876.
Antonucci S, Di Sante M, Sileikyte J, et al. A novel class of cardioprotective small‐molecule PTP inhibitors. Pharmacol Res. 2020;151:104548.
Fancelli D, Abate A, Amici R, et al. Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia‐reperfusion injury protective effect in vivo. J Med Chem. 2014;57(12):5333‐5347.
Chen Z, Tan X, Jin T, et al. Pharmaceutical manipulation of mitochondrial F0F1‐ATP synthase enables imaging and protection of myocardial ischemia/reperfusion injury through stress‐induced selective enrichment. Adv Sci (Weinh). 2024;11(9):e2307880.
Mendoza A, Patel P, Robichaux D, Ramirez D, Karch J. Inhibition of the mPTP and lipid peroxidation is additively protective against I/R injury. Circ Res. 2024;134(10):1292‐1305.